BMC Cancer

1. CAI X, Lin J, Liu L, Zheng J, et al
   A novel TCGA-validated programmed cell-death-related signature of ovarian cancer.
   BMC Cancer. 2024;24:515.
   

   >> Share

   
   

   
   Br J Cancer

2. DHAR C, Ramachandran P, Xu G, Pickering C, et al
   Diagnosing and staging epithelial ovarian cancer by serum glycoproteomic profiling.
   Br J Cancer. 2024 Apr 24. doi: 10.1038/s41416-024-02644.
   

   >> Share

   
   

   
   Cancer Chemother Pharmacol

3. LEE IH, Lee SJ, Kim J, Lee YH, et al
   Exploring the effect of BRCA1/2 status on chemotherapy-induced hematologic toxicity in patients with ovarian cancer.
   Cancer Chemother Pharmacol. 2024 Apr 23. doi: 10.1007/s00280-024-04670.
   

   >> Share

   
   

   
   Cancer Lett

4. HA JH, Radhakrishnan R, Nadhan R, Gomathinayagam R, et al
   Deciphering a GPCR-lncRNA-miRNA Nexus: Identification of an Aberrant Therapeutic Target in Ovarian Cancer.
   Cancer Lett. 2024 Apr 18:216891. doi: 10.1016/j.canlet.2024.216891.
   

   >> Share

   
   

   
   Eur J Obstet Gynecol Reprod Biol

5. HU D, Qian J, Yin F, Wei B, et al
   Evaluation of serum CA125, HE4 and CA724 and the risk of ovarian malignancy algorithm score in the diagnosis of high-grade serous ovarian cancer.
   Eur J Obstet Gynecol Reprod Biol. 2024;297:170-175.
   

   >> Share

   
   

   
   Histopathology

6. PARRA-HERRAN C, Dundr P, McCluggage WG
   Editorial: Infiltrative pattern of invasion is independently associated with shorter survival and desmoplastic stroma markers FAP and THBS2 in mucinous ovarian carcinoma.
   Histopathology. 2024;84:1092-1094.
   

   >> Share

   
   
7. KOBEL M, Kang EY, Lee S, Terzic T, et al
   Infiltrative pattern of invasion is independently associated with shorter survival and desmoplastic stroma markers FAP and THBS2 in mucinous ovarian carcinoma.
   Histopathology. 2024;84:1095-1110.
   

   >> Share

   
   

   
   Int J Gynecol Pathol

8. ALROHAIBANI A, Yu Y, Gao L, McLean KM, et al
   PReferentially Expressed Antigen in MElanoma Expression in Uterine and Ovarian Carcinosarcomas.
   Int J Gynecol Pathol. 2024;43:284-289.
   

   >> Share

   
   
9. YAMAMOTO A, Nagai T, Sukeda A, Kajiwara M, et al
   Ovarian Mesonephric-like Adenocarcinoma Recurring With a Rhabdomyosarcoma Component: A Case Report.
   Int J Gynecol Pathol. 2024;43:296-301.
   

   >> Share

   
   
10. LI Y, Chen J, Niu S
    Endometrioid Adenocarcinoma With "Burrowing" Invasion of the Cervix Represents a Separate Primary From the Concurrent Uterine Corpus Endometrial Endometrioid Adenocarcinoma: Histology, Immunohistochemistry, and Next-generation Sequencing Study of a Si
    Int J Gynecol Pathol. 2024;43:271-274.
    

    >> Share

    
    
11. XU J, Weisman PS
    Divergent Malignant Melanocytic Differentiation in Ovarian Endometrioid Adenocarcinoma With Aberrant beta-Catenin Expression: A Case Expanding the Histologic Spectrum of beta-Catenin Activated Gynecologic Neoplasia.
    Int J Gynecol Pathol. 2024;43:302-307.
    

    >> Share

    
    
12. JU B, Wu J, Sun L, Yang C, et al
    Molecular Classification of Endometrial Endometrioid Carcinoma With Microcystic Elongated and Fragmented Pattern.
    Int J Gynecol Pathol. 2024;43:233-241.
    

    >> Share

    
    
13. LEE Y, Choi S, Kim HS
    Comprehensive Immunohistochemical Analysis of Mesonephric Marker Expression in Low-grade Endometrial Endometrioid Carcinoma.
    Int J Gynecol Pathol. 2024;43:221-232.
    

    >> Share

    
    

    
    Obstet Gynecol

14. LEE MW, Anderson ZS, Girma AM, Klar M, et al
    Diagnosis Shift in Site of Origin of Tubo-Ovarian Carcinoma.
    Obstet Gynecol. 2024 Mar 21. doi: 10.1097/AOG.0000000000005562.
    

    >> Share

    
    

    
    Oncogene

15. SHAN W, Peng W, Chen Y, Wang Y, et al
    GSK3beta and UCHL3 govern RIPK4 homeostasis via deubiquitination to enhance tumor metastasis in ovarian cancer.
    Oncogene. 2024 Apr 25. doi: 10.1038/s41388-024-03040.
    

    >> Share

    
    

    
    Semin Oncol

16. LAROSE M, Manji GA, Bates SE
    Beyond BRCA: Diagnosis and management of homologous recombination repair deficient pancreatic cancer.
    Semin Oncol. 2024;51.
    

    >> Share

    
    
17. ZENG Y, Arisa O, Peer CJ, Fojo A, et al
    PARP inhibitors: A review of the pharmacology, pharmacokinetics, and pharmacogenetics.
    Semin Oncol. 2024;51.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share